<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112435</url>
  </required_header>
  <id_info>
    <org_study_id>14-011-CERES-D</org_study_id>
    <secondary_id>NH-14SRP-Somnyx</secondary_id>
    <nct_id>NCT02112435</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy Study of Titratable Versus Active Mandibular Advancement Splint in Sleep Apnea</brief_title>
  <acronym>SOMNYX</acronym>
  <official_title>Comparative Study of Efficacy of Titratable Mandibular Advancement Splint Versus Active Mandibular Advancement Splint to Treat Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep apnea is a common disorder that occurs in 3-10 % of the adult population. This disorder
      disrupts the architecture and quality of sleep. Continuous positive airway pressure (CPAP)
      therapy is the standard treatment, but in some cases, it can not be used (patient refusal or
      intolerance). In these cases, treatment with mandibular advancement devices can bring an
      improvement in symptoms. Therefore, this study aims to compare the effectiveness of
      titratable versus active mandibular advancement splints in standard care environment. This
      will be based on the global response, which includes the apnea-hypopnea index and compliance
      in severe apnea patients who refused or where intolerant to CPAP. Following their severe
      apnea diagnosis and the assessment on the feasibility of placing a mandibular advancement
      device, follow-up visits will be scheduled after 3 months of treatment involving clinical
      monitoring by a physician and a dentist.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>following 3 months of treatment</time_frame>
    <description>Overall response rate (ORR) = rate of complete response (TRc) + partial response rate (PRR) =% of patients with AHI &lt;15 or ≥ 50% reduction in AHI and compliance ≥ 5 nights / week and 5 hours / night</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response</measure>
    <time_frame>following 3 months of treatment</time_frame>
    <description>Rate of Complete Response (TRc) =% Patients with AHI &lt;15 and AHI ≥ 50% reduction and compliance ≥ 5 nights / week and 5 hours / night)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Partial response rate =% of patients with reduction AHI ≥ 50% with AHI&gt; 15 or AHI &lt;15 with reduction &lt;50% and adherence ≥ 5 nights / week and 5 hours / night) at 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective compliance</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Subjective compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>sleep efficiency, total sleep time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>desaturation index, time spent below 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleep</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Pittsburgh questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Functional outcomes sleep questionnaire (FOSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Chalder fatigue questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective daytime sleepiness</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>Epworth sleepiness score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Following 3 months of treatment</time_frame>
    <description>side effects and interactions with the dental evaluations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Narval ORM ® or SomnoDent ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mandibular advancement splint (Narval ORM ® or SomnoDent ®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somnyx ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active mandibular advancement splint (Somnyx ®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Somnyx ®</intervention_name>
    <description>Active mandibular advancement splint</description>
    <arm_group_label>Somnyx ®</arm_group_label>
    <other_name>Active mandibular advancement appliance</other_name>
    <other_name>Oral appliance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narval ORM ® or SomnoDent ®</intervention_name>
    <description>Mandibular advancement splint</description>
    <arm_group_label>Narval ORM ® or SomnoDent ®</arm_group_label>
    <other_name>Mandibular advancement splint</other_name>
    <other_name>Mandibular advancement appliance</other_name>
    <other_name>Oral appliance</other_name>
    <other_name>Mandibular repositioning appliance</other_name>
    <other_name>Mandibular repositioning splint</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 65 years

          -  severe OSA confirmed by polysomnography (PSG) is: 30&gt; AHI&gt; 15 with severe daytime
             sleepiness - Epworth ≥ 10 or AHI&gt; 30

          -  patient in failure or refusal of CPAP treatment

          -  agree to participate and sign the consent form research

          -  speak and understand French without external assistance

          -  be in good health (no neurological or psychiatric syndrome).

          -  have a valid Social Security card (in France and Portugal only)

        Exclusion Criteria:

          -  contra-indicated dental/periodontal states for mandibular advancement splints, such
             as: 1) significant edentulism (less than 3 healthy teeth / quadrant), 2) generalized
             periodontitis or severe parodonthopathies, 3) severe disorders of the
             temporomandibular joint (TMJ), 4) less than 5 mm of maximal mandibular protrusion

          -  dental restorations in progress or planned in the next 6 months

          -  psychiatric and neuromuscular disorders

          -  untreated cardiovascular diseases and history of stroke or myocardial infarction

          -  severe or morbid obesity (body mass index&gt; 35)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Huynh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelly Huynh, PhD</last_name>
    <email>nelly.huynh@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles Lavigne, DMD, PhD</last_name>
    <email>gilles.lavigne@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3C3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly Huynh, PhD</last_name>
      <email>nelly.huynh@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Gilles Lavigne, DMD, PhD</last_name>
      <email>gilles.lavigne@umontreal.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Nelly Huynh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Lavigne, DMD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Dauvilliers, MD</last_name>
      <email>y-dauvilliers@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Dauvilliers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Gallet de Santerre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Bonafé, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Philippe, MD</last_name>
      <email>carole.philippe@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Carole Philippe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie Attalie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéfania Redolfi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Arnulf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Collet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Goudot, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Montréal</investigator_affiliation>
    <investigator_full_name>Nelly Huynh</investigator_full_name>
    <investigator_title>Assistant research professor</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>mandibular advancement splint</keyword>
  <keyword>active mandibular advancement splint</keyword>
  <keyword>oral appliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

